Health Care [ 6/12 ] | Health Care Equipment & Supplies [ 26/75 ]
NASDAQ | Common Stock
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases.
The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves.
The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally.
The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013.
Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | -0.36 Increased by +7.69% | -0.45 Increased by +20.00% |
| Jul 31, 24 | -0.35 Increased by +18.60% | -0.43 Increased by +18.60% |
| May 1, 24 | -0.36 Increased by +14.29% | -0.46 Increased by +21.74% |
| Feb 21, 24 | -0.36 Increased by +5.26% | -0.41 Increased by +12.20% |
| Oct 30, 23 | -0.39 Decreased by -2.63% | -0.43 Increased by +9.30% |
| Aug 2, 23 | -0.43 Decreased by -7.50% | -0.44 Increased by +2.27% |
| May 2, 23 | -0.42 Increased by +2.33% | -0.44 Increased by +4.55% |
| Feb 22, 23 | -0.38 Decreased by -8.57% | -0.42 Increased by +9.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 20.39 M Increased by +15.39% | -14.14 M Increased by +5.07% | Decreased by -69.38% Increased by +17.73% |
| Jun 30, 24 | 20.78 M Increased by +20.87% | -15.33 M Increased by +5.37% | Decreased by -73.74% Increased by +21.71% |
| Mar 31, 24 | 18.85 M Increased by +29.71% | -13.75 M Increased by +13.31% | Decreased by -72.92% Increased by +33.17% |
| Dec 31, 23 | 19.28 M Increased by +24.98% | -13.89 M Increased by +2.77% | Decreased by -72.04% Increased by +22.20% |
| Sep 30, 23 | 17.67 M Increased by +30.85% | -14.90 M Decreased by -8.06% | Decreased by -84.33% Increased by +17.42% |
| Jun 30, 23 | 17.19 M Increased by +23.25% | -16.20 M Decreased by -10.62% | Decreased by -94.19% Increased by +10.25% |
| Mar 31, 23 | 14.54 M Increased by +34.77% | -15.86 M Decreased by -0.20% | Decreased by -109.12% Increased by +25.65% |
| Dec 31, 22 | 15.43 M Increased by +12.53% | -14.28 M Decreased by -9.82% | Decreased by -92.60% Increased by +2.41% |